Compugen Reports First Quarter 2021 Results
Compugen Reports First Quarter 2021 Results USA - English Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Milestone rich 2021 to include data readouts from ongoing COM701 triple combination study and COM902 monotherapy study in Q4 2021 Initiation of Phase 1b cohort expansion study of COM701 with Opdivo® in Q2 2021 and Phase 1 COM701 with COM902 dual combination study in 2H 2021 will expand systematic DNAM axis clinical evaluation News provided by Share this article Share this article ...
Source: prnewswire.com